Clinical Trial Update: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Platform Phase 1/2 trial evaluating neoadjuvant regimens containing trastuzumab deruxtecan for HER2-positive, resectable esophagogastric adenocarcinoma; the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Adenocarcinoma

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Esophagogastric Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING